Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:19:11 EST Wed 14 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:PFE - PFIZER INC - https://www.pfizer.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PFE - Z1.025.14·25.160.325.157.117559    27.69  20.91505:54:36Jan 1015 min RT 2¢

Recent Trades - Last 10 of 59
Time ETExPriceChangeVolume
05:54:36Z25.15 40
05:50:54Z25.15 137
05:50:49Z25.15 176
05:50:45Z25.15 250
05:47:08Z25.15 60
05:45:52Z25.160.015
05:44:43Z25.15 50
05:44:43Z25.15 37
05:36:48Z25.160.0120
05:35:25Z25.15 1

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-10 10:00U:PFENews ReleasePfizer's BRAFTOVI(TM) Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
2026-01-05 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2025-12-18 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
2025-12-17 06:45U:PFENews ReleasePADCEV(TM) Plus Keytruda(TM) Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
2025-12-16 06:45U:PFENews ReleasePfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
2025-12-15 08:00U:PFENews ReleaseAdaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
2025-12-12 12:00U:PFENews ReleasePfizer Declares First-Quarter 2026 Dividend
2025-12-10 08:15U:PFENews ReleaseTUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
2025-12-09 06:30U:PFENews ReleasePfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
2025-12-06 17:15U:PFENews ReleaseHYMPAVZI(TM) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
2025-12-01 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
2025-11-24 07:00U:PFENews ReleaseArvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
2025-11-21 13:24U:PFENews ReleaseU.S. FDA Approves PADCEV(TM) plus Keytruda(TM) for Certain Patients with Bladder Cancer
2025-11-13 11:26U:PFENews ReleasePfizer Completes Acquisition of Metsera
2025-11-12 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2025-11-05 17:08U:PFENews ReleasePfizer Responds to Delaware Chancery Court Ruling
2025-11-04 06:45U:PFENews ReleasePfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
2025-11-03 07:57U:PFENews ReleasePfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
2025-10-31 16:37U:PFENews ReleasePfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
2025-10-31 15:50U:PFENews ReleasePfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition